Effective CAR T-cell targeting of an MUC1 cleavage product

These results support that the combination of targeting MUC1*, the growth factor receptor form of MUC1, with a CAR T bearing the 1XX mutations in CD3ζ has therapeutic potential for the treatment of solid tumor cancers.